OncoQuest Pharmaceuticals Inc (078590) - Total Liabilities
Based on the latest financial reports, OncoQuest Pharmaceuticals Inc (078590) has total liabilities worth ₩19.38 Billion KRW (≈ $13.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 078590 net asset momentum to track the company's year-over-year net asset growth rate.
OncoQuest Pharmaceuticals Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how OncoQuest Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See 078590 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
OncoQuest Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of OncoQuest Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DocCheck AG
XETRA:AJ91
|
Germany | €14.07 Million |
|
Marchex Inc
NASDAQ:MCHX
|
USA | $9.60 Million |
|
TPL Plastech Limited
NSE:TPLPLASTEH
|
India | Rs976.82 Million |
|
Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme
AT:MOTO
|
Greece | €54.21 Million |
|
Johnson Chemical Pharmaceutical Works Co Ltd
TWO:4747
|
Taiwan | NT$279.70 Million |
|
Next Technology Holding Inc
NASDAQ:NXTT
|
USA | $40.37 Million |
|
Hwa Sung Ind
KO:002460
|
Korea | ₩304.28 Billion |
|
Vitura S.A.
PA:VTR
|
France | €672.77 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down OncoQuest Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 078590 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OncoQuest Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OncoQuest Pharmaceuticals Inc (2014–2025)
The table below shows the annual total liabilities of OncoQuest Pharmaceuticals Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩32.66 Billion ≈ $22.14 Million |
+19.23% |
| 2024-12-31 | ₩27.40 Billion ≈ $18.57 Million |
+154.34% |
| 2023-12-31 | ₩10.77 Billion ≈ $7.30 Million |
+15.50% |
| 2022-12-31 | ₩9.33 Billion ≈ $6.32 Million |
-80.24% |
| 2019-12-31 | ₩47.21 Billion ≈ $31.99 Million |
+7.42% |
| 2018-12-31 | ₩43.95 Billion ≈ $29.78 Million |
+330.22% |
| 2017-12-31 | ₩10.21 Billion ≈ $6.92 Million |
+40.75% |
| 2016-12-31 | ₩7.26 Billion ≈ $4.92 Million |
+5.27% |
| 2015-12-31 | ₩6.89 Billion ≈ $4.67 Million |
-28.24% |
| 2014-12-31 | ₩9.61 Billion ≈ $6.51 Million |
-- |
About OncoQuest Pharmaceuticals Inc
DIAC Co., Ltd. engages in the car interior and exterior materials business in South Korea and internationally. DIAC Co., Ltd. was founded in 1993 and is headquartered in Miryang-si, South Korea.